Adial Pharmaceuticals Inc. (NASDAQ:ADIL) and Odonate Therapeutics Inc. (NASDAQ:ODT) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adial Pharmaceuticals Inc. | 2 | 0.00 | N/A | -2.27 | 0.00 |
| Odonate Therapeutics Inc. | 28 | 0.00 | N/A | -4.46 | 0.00 |
Table 1 highlights Adial Pharmaceuticals Inc. and Odonate Therapeutics Inc.’s gross revenue, earnings per share and valuation.
Profitability
Table 2 provides Adial Pharmaceuticals Inc. and Odonate Therapeutics Inc.’s net margins, return on assets and return on equity.
| Net Margins | Return on Equity | Return on Assets | |
| Adial Pharmaceuticals Inc. | 0.00% | -281.4% | -251.1% |
| Odonate Therapeutics Inc. | 0.00% | -78% | -68.4% |
Liquidity
The Current Ratio and Quick Ratio of Adial Pharmaceuticals Inc. are 36.6 and 36.6 respectively. Its competitor Odonate Therapeutics Inc.’s Current Ratio is 9.6 and its Quick Ratio is 9.6. Adial Pharmaceuticals Inc. can pay off short and long-term obligations better than Odonate Therapeutics Inc.
Analyst Ratings
The following table delivered below contains the ratings and recommendations for Adial Pharmaceuticals Inc. and Odonate Therapeutics Inc.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Adial Pharmaceuticals Inc. | 0 | 0 | 0 | 0.00 |
| Odonate Therapeutics Inc. | 1 | 0 | 0 | 1.00 |
Competitively Odonate Therapeutics Inc. has a consensus target price of $10, with potential downside of -64.55%.
Institutional and Insider Ownership
Roughly 16.8% of Adial Pharmaceuticals Inc. shares are held by institutional investors while 83.5% of Odonate Therapeutics Inc. are owned by institutional investors. About 3.4% of Adial Pharmaceuticals Inc.’s share are held by insiders. Comparatively, insiders own roughly 0.1% of Odonate Therapeutics Inc.’s shares.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Adial Pharmaceuticals Inc. | -9.55% | 6.51% | -33.82% | -67.15% | -55.07% | -64.84% |
| Odonate Therapeutics Inc. | 21.28% | 8.9% | 135.96% | 150.77% | 100.89% | 189.42% |
For the past year Adial Pharmaceuticals Inc. has -64.84% weaker performance while Odonate Therapeutics Inc. has 189.42% stronger performance.
Summary
Odonate Therapeutics Inc. beats on 5 of the 7 factors Adial Pharmaceuticals Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
